Gabinete Ventilado

Informação básica

• Disponível em:
• Português
• English

Introducing EarlyTect Colon Cancer Test, a groundbreaking medical advancement in the field of colorectal cancer diagnosis. This product has been meticulously developed and rigorously tested, gaining approval from the Korea Ministry of Food and Drug Safety.

Clinical trials were conducted at prestigious medical institutions, including Yonsei Medical Center, Severance Hospital, and Severance Check-up Center. The trials involved 585 men and women, ranging from 30 to 80 years old, who met the eligibility criteria. The results were remarkable - the EarlyTect Colon Cancer Test exhibited a sensitivity and specificity of 90%, providing an accurate diagnosis for colorectal cancer.

This qualitative real-time PCR test focuses on measuring methylated Syndecan-2, a clinically relevant biomarker associated with precancerous lesions of colorectal cancer. By examining stool DNA, this test enables healthcare professionals to identify the presence of colorectal cancer with precision.

It is important to note that the EarlyTect Colon Cancer Test is not intended to confirm the presence of colorectal cancer itself. However, a positive result from this test suggests the potential existence of colorectal cancer or precancerous lesions. In such cases, further evaluation and confirmation are necessary.

Product Standard:
- Cancer Type: Colorectal Cancer
- Targeted Subjects: Asymptomatic individuals undergoing colorectal cancer screening
- Biomarker: SDC2 mRNA

The price and transaction conditions for the EarlyTect Colon Cancer Test are open for negotiation. To receive a detailed quote or initiate a transaction, kindly submit a request through our dedicated platform.